Article
FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.
Leukemia - 1 Feb 2024
Sung Pamela J, Selvam Murugan, Riedel Simone S, Xie Hongbo M, Bryant Katie, Manning Bryan, Wertheim Gerald B, Kulej Katarzyna, Pham Lucie, Bowman Robert L, Peresie Jennifer, Nemeth Michael J, Levine Ross L, Garcia Benjamin A, Meyer Sara E, Sidoli Simone, Bernt Kathrin M, Carroll Martin
Abstract excerpt
Internal tandem duplication mutations in fms-like tyrosine kinase 3 (FLT3-ITD) are recurrent in acute myeloid leukemia (AML) and increase the risk of relapse. Clinical responses to FLT3 inhibitors (FLT3i) include myeloid differentiation of the FLT3-ITD clone in nearly half of patients through an unknown mechanism. We identified enhancer of zeste homolog 2 (EZH2), a component of polycomb repressive complex 2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.